BOSTON SCIENTIFIC CORP (NYSE:BSX) stands out as a compelling candidate for high-growth momentum investors, combining strong earnings momentum with a favorable technical setup. The company, a leader in medical device innovation, has demonstrated consistent growth in earnings and revenue while presenting a well-defined consolidation pattern on the charts.
Growth Momentum Highlights
Earnings Growth: BSX reported a 26.2% year-over-year EPS growth (TTM), with recent quarterly EPS growth accelerating to 33.9%.
Revenue Strength: Sales growth remains robust, with a 19.4% increase over the past year and a 20.9% jump in the most recent quarter.
Profit Margin Expansion: The company has improved its quarterly profit margin from 7.9% a year ago to 14.5% in the latest quarter.
Positive Revisions: Analysts have raised next-year EPS estimates by 2.0% over the past three months, reflecting confidence in continued growth.
Consistent Earnings Beats: BSX has surpassed EPS estimates in each of the last four quarters, with an average beat of 7.1%.
Technical Strength & Setup
Technical Rating (7/10): BSX maintains a solid uptrend, outperforming 83% of its peers in the Health Care Equipment & Supplies industry.
Setup Rating (8/10): The stock is consolidating within a defined range ($100.34 - $107.53), offering a potential breakout opportunity.
Support & Resistance: Key support lies near $102.61, while resistance sits around $103.69. A breakout above resistance could signal further upside.
Recent Pocket Pivot: A bullish accumulation signal was recently detected, reinforcing the positive setup.